Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
NAPROXEN DELAYED-RELEASE TABLETS USP10051006Rx only
Medication labelWhy this: Advisory · dailymed-prescription
Carefully consider the potential benefits and risks of Naproxen Delayed-Release Tablets USP and other treatment options before deciding to use Naproxen Delayed-Release Tablets USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen Delayed-Release Tablets USP are indicated: For the relief of the signs and symptoms of rheumatoid arthritis For the relief of the signs and symptoms of osteoarthritis For the relief of the signs and symptoms of ankylosing spondylitis For the relief of the signs and symptoms of juvenile arthritis Naproxen, USP as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. Naproxen Delayed-Release Tablets USP are not recommended for initial treatment of acute pain because the absorption of naproxen, USP is delayed compared to absorption from other naproxen-containing products (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION ).
- generic_name
- naproxen
- product_names
- Naproxen
- ndc
- 33261-082, 0093-1005, 33261-082-60, 33261-083, 0093-1006, 33261-083-30, 33261-083-60
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en